Children's Product Safety Home

Product Details

Product name Aprepitant capsules and Lidocaine and Prilocaine cream
Description This recall involves prescription drugs Aprepitant 125 mg capsules sold in cartons containing one blister card of 6 capsules and 5 gram tubes of Lidocaine and Prilocaine cream sold in cartons containing 5 tubes and packed with or without 12 dressings. The Aprepitant capsules are in a non-child resistant blister card packaged in a carton that has the name Sandoz, the name of the medication, dosage, NDC number, lot number, and expiration date on the carton and on the blister cards. The warnings This unit-dose packaging is not child-resistant and For institutional use only are listed on the carton. The Lidocaine and Prilocaine cream is packaged in a 5 gram tube with a continuous thread white closure. The name fougeraŽ, the name of the medication, dosage and NDC number are printed on the carton and tube and the expiration date and lot number are printed on the carton and stamped on the crimp of the tube. The warning FOR HOSPITAL USE ONLY is printed on the carton and the tube. See the news release below for a list of products included in this recall. 
Problem The recalled prescription drugs and products that contain lidocaine must be in child resistant packaging as required by the Poison Prevention Packaging Act (PPPA). The packaging of the products is not child resistant, posing a risk of poisoning if the contents are swallowed by young children. 
Distribution Pharmacies nationwide as a prescribed medicine. The prices of the medications varied based on health insurance terms and other factors. 
Company Sandoz 866-300-2207; web page or 
Dates sold October 2020 through January 2023 
Date posted 03/09/2023 
Additional information For additional information, visit the U.S. Consumer Product Safety Commission's news release at 

Home   Back

idph online home
Illinois Department of Public Health
535 West Jefferson Street
Springfield, Illinois 62761
Phone 217-782-3300
Fax 217-782-3987
TTY 800-547-0466
Questions or Comments